RxDoctor Payments Data

Phillip Suwan, MD

Interventional Pain Medicine · Aiken, SCNPI 1043473895

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,798 of the $5,951 with a category attached, or 80.6%. Medtronic accounts for 64.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $2,585 and has fallen 86.8% since, to $341 in 2025.

$5,951in general payments, 2019–2025

Across 150 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$533
  • Nevro Corp.$532
  • Tersera Therapeutics LLC$427
  • Scilex Pharmaceuticals Inc.$375
  • Abbott$61
  • plus $182 from 8 others

What the payments were for

  • Travel & lodging$1,09418%
  • Food & beverage$4,79881%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,951 in reported general payments places this provider in the 75th percentile of 38 interventional pain medicine providers in South Carolina.

See all interventional pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$454,509
Medicare patients
587
Services billed
5,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine48$33,447
Calcipotriene-BetamethasoneCalcipotriene/Betamethasone23$30,040
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,024$24,711
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen380$9,410
Diflorasone Diacetate11$8,834
Pregabalin458$6,760
Gabapentin479$6,185
Clobetasol Propionate41$5,936
Methocarbamol419$5,437
Celecoxib98$4,055
Acetaminophen-CodeineAcetaminophen With Codeine202$3,688
Tizanidine Hcl217$3,398
Cyclobenzaprine Hcl130$2,509
Halobetasol Propionate15$2,492
Tramadol Hcl252$1,881

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$375$33,44748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 38 interventional pain medicine providers in South Carolina.

Other interventional pain medicine in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →